Among nearly 8,600 people living with type 2 diabetes in Eastern Finland, a quiet failure of care has been documented: those most in need of cholesterol-lowering treatment received it least, and women — carrying higher cholesterol burdens than their male counterparts — were systematically undertreated across every patient group. The study, spanning five years of clinical records, places this not as an anomaly but as a pattern, one that widens the distance between what medicine knows and what medicine does.
Study reveals gaps in type 2 diabetes care, with women undertreated for cholesterol
Women had higher cholesterol but received treatment less often
Mark
So this study looked at nearly 8,600 patients over five years. What was the main finding?
Mimi
That a significant portion of type 2 diabetes patients with persistently high cholesterol weren't receiving statin treatment, and women were being undertreated compared to men across the board.
Luke
How do we know the cholesterol was actually persistently high? Did they measure it consistently across all patients?
Mimi
The researchers tracked LDL-C values over time and identified trajectory groups. The "high-stable" group had cholesterol around 3.9 mmol/L that didn't improve.
Mark
And what happened to statin prescriptions in that high-stable group?
Mimi
They actually declined. For men, prescriptions dropped from 42 percent to 27 percent between 2012 and 2017. For women, from 34 percent to 23 percent.
Luke
That's a significant drop. But do we know why? Was it patient non-compliance, physician choice, insurance barriers?
Mimi
The study doesn't explain the reasons for the decline—it documents the pattern. The researchers note there are gaps in current diabetes management but don't dig into the causes.
Mark
What about the gender difference? Why would women have higher cholesterol but receive less treatment?
Mimi
That's the question the study raises but doesn't fully answer. Women had higher average LDL-C levels across all groups and received both any statin treatment and high-intensity treatment less frequently.
Luke
Is it possible the women in the study had different baseline characteristics—age, other conditions, medication interactions—that might explain some of the difference?
Mimi
The study doesn't provide that level of detail. It identifies the disparity but leaves the mechanism unclear.
Mark
So what's the takeaway for patients and doctors?
Mimi
The researchers suggest healthcare systems need to initiate statin treatment earlier, intensify it when cholesterol stays high, and restart it when patients have stopped. The gap between guidelines and actual practice is real and needs closing.
O Pulso
- A group of patients with chronically elevated cholesterol — never improving over five years — saw statin prescriptions fall sharply rather than rise, dropping from 42% to 27% in men and from 34% to 23% in women.
- Women across all cholesterol trajectory groups carried higher LDL levels than men yet received both standard and high-intensity statin therapy less frequently, revealing a gender gap that cuts across the entire care system.
- Clear clinical guidelines already recommend moderate- to high-intensity statin treatment for type 2 diabetes patients with elevated cholesterol, making the shortfall a matter of implementation, not knowledge.
- The uncontrolled cholesterol left in place by undertreament keeps patients on a direct path toward coronary artery disease, heart failure, and stroke — the very complications that type 2 diabetes already makes more likely.
- Researchers are calling on healthcare systems to initiate statin therapy earlier, intensify it when cholesterol persists, and prioritize closing the treatment gap for women before it costs lives.
Among nearly 8,600 people living with type 2 diabetes in Eastern Finland, a quiet failure of care has been documented: those most in need of cholesterol-lowering treatment received it least, and women — carrying higher cholesterol burdens than their male counterparts — were systematically undertreated across every patient group. The study, spanning five years of clinical records, places this not as an anomaly but as a pattern, one that widens the distance between what medicine knows and what medicine does.
Type 2 diabetes already raises the stakes for the heart — elevating the risk of heart attack, heart failure, and early death. Managing cholesterol is one of the clearest tools available to reduce that risk. But a five-year study of 8,592 diabetes patients in North Karelia, Finland, found that the patients who needed that tool most were the least likely to receive it.
Researchers at the University of Eastern Finland sorted patients by how their cholesterol levels moved over time. The majority — 86 percent — held relatively stable, moderate levels. But 8 percent showed a more troubling pattern: persistently high cholesterol hovering around 3.9 mmol/L with no improvement across the study period. For this group, aggressive treatment should have been most visible. Instead, statin prescriptions declined. Men in this category saw their treatment rates fall from 42% to 27% between 2012 and 2017; women fell from 34% to 23%.
The gender disparity did not stop at the high-stable group. Across every cholesterol trajectory, women averaged higher LDL levels than men — yet received statin therapy, at any intensity, less frequently. Researcher Laura Inglin described the finding directly: women had significantly higher cholesterol and significantly less treatment, in every group studied.
What makes the findings particularly pointed is that the guidelines are not ambiguous. The evidence for statin use in this population is well established. The gap is not one of scientific uncertainty but of clinical practice — of what gets prescribed at the bedside versus what the evidence recommends. The researchers argue that healthcare systems must act more decisively: starting treatment earlier, intensifying it when cholesterol remains elevated, and restoring it when patients have drifted away. For women especially, the data makes a quiet but urgent case for change.
Type 2 diabetes carries a heavy cardiovascular price. Patients with the condition face elevated risk of heart attack, heart failure, and early death—threats that can be substantially reduced through careful management of blood sugar and cholesterol levels. Yet a study of nearly 8,600 diabetes patients in Eastern Finland reveals that many are not receiving the cholesterol treatment they need, and women are being undertreated at notably higher rates than men.
Researchers at the University of Eastern Finland examined electronic health records from 8,592 type 2 diabetes patients who received care between 2012 and 2017 in North Karelia. They tracked cholesterol levels over time and sorted patients into groups based on their patterns. Most patients—86 percent—maintained moderate cholesterol levels that remained relatively stable. But a smaller group, representing 8 percent of the cohort, presented a troubling picture: persistently elevated cholesterol around 3.9 mmol/L that never improved. This "high-stable" group was precisely where aggressive treatment should have been most evident. Instead, it was nearly absent.
Among patients with chronically high cholesterol, statin prescriptions declined sharply over the five-year study period. For men in this group, the proportion receiving any statin therapy dropped from 42 percent in 2012 to 27 percent by 2017. Women fared even worse, falling from 34 percent to 23 percent. These are not marginal differences. They represent hundreds of patients whose cholesterol remained uncontrolled despite clear clinical guidelines recommending moderate- to high-intensity statin treatment for people with type 2 diabetes and elevated cholesterol.
The gender disparity extended across all patient groups, not just those with persistently high levels. Women consistently showed higher average cholesterol readings than men, yet received statin treatment—whether at any dose or at high intensity—significantly less often. Laura Inglin, an early-stage researcher on the study, noted the pattern plainly: "In all the trajectory groups, women had significantly higher average LDL-C levels and received any statin treatment and high-intensity treatment less frequently than men."
The findings point to systemic gaps in how diabetes care is delivered in clinical practice. Guidelines exist and are clear. The evidence supporting statin use in this population is robust. Yet the actual treatment being prescribed falls short, particularly for women. The researchers identified what they call "significant heterogeneity" in care—meaning patients are receiving wildly different treatments depending on factors that have nothing to do with their actual cholesterol levels or cardiovascular risk.
The implications are concrete. Patients with persistently elevated cholesterol who are not on statins remain at high risk for the very complications that type 2 diabetes makes likely: coronary artery disease, heart failure, stroke. The study suggests that healthcare systems need to act more decisively—initiating statin treatment earlier, intensifying it when cholesterol remains high, and restarting it when patients have stopped taking it. For women especially, the data suggests a need to close the gap between clinical guidelines and what is actually being prescribed at the bedside.
Citações Notáveis
In all the trajectory groups, women had significantly higher average LDL-C levels and received any statin treatment and high-intensity treatment less frequently than men.— Laura Inglin, Early Stage Researcher, University of Eastern Finland
Quer a matéria completa?
Leia o original em News-Medical.net ↗
Health & Medicine